The primary regulator of megakaryocytopoiesis and platelet formation is thrombopoietin (TPO). The CD110 protein, which is 635 amino acids long and has two extracellular cytokine receptor domains and two intracellular cytokine receptor box motifs, is encoded by the c-mpl gene. The JAK family of non-receptor tyrosine kinases, the STAT family, the MAPK family, the adaptor protein Shc, and the receptors themselves are all tyrosine phosphorylated upon binding of thrombopoietin to CD110.
TPO binds to the thrombopoietin receptor (TPOr, also known as c-mpl) on platelets, megakaryocytes, and pluripotent stem cells. This inhibits the death of stem cells and megakaryocytes, increases the number, size, and ploidy of megakaryocytes, speeds up megakaryocyte maturation and platelet count, and lowers the threshold for ADP and collagen activation of platelets.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V74333 | Avatrombopag hydrochloride (AKR-501 hydrochloride; E5501 hydrochloride; YM477 hydrochloride) | 570403-17-7 | Avatrombopag (AKR-501) HCl is an orally bioactive, non-peptide thrombopoietin receptor (TPO receptor) agonist (EC50=3.3 nM). |
|
V74335 | Eltrombopag methyl ester | 1246929-01-0 | Eltrombopag methyl ester is an Eltrombopag analogue, a thrombopoietin (Tpo) receptor agonist that promotes platelet production and may be used in studies related to specific types of thrombocytopenia. |
|
V74334 | Rafutrombopag | 2600513-51-5 | Rafutrombopag is a thrombopoietin (TPO) agonist disclosed in patent CN113929668. |
|
V1896 | Eltrombopag (SB-497115) | 496775-61-2 | Eltrombopag (formerly SB-497115; SB 497115; SB497115; trade name PROMACTA), a member of the biarylhydrazone class, is a novel nonpeptide agonist of the thrombopoietin receptor (TpoR) approved for use in the treatment of chronic hepatitis C-associated thrombocytopenia and chronic immune (idiopathic) thrombocytopenia (ITP). |
|
V2054 | Eltrombopag Olamine (SB-497115GR) | 496775-62-3 | Eltrombopag Olamine (SB-497115-GR, SB497115; trade names: Promacta; Revolade), the olamine salt ofEltrombopag which is a member of the biarylhydrazone compounds, is a nonpeptide agonist of the thrombopoietin receptor (TpoR) approved as a medication to treat thrombocytopenia and severe aplastic anemia. |
|
V3880 | lusutrombopag | 1110766-97-6 | Lusutrombopag (formerly known as S888711; S-888711;trade name:Mulpleta) is a novel orally bioavailable, small molecule agonist of thrombopoietin (TPO) receptor. |
|
V3891 | Avatrombopag | 570406-98-3 | Avatrombopag (formerly AKR-501, YM-477, AS-1670542; E-5501; trade name:Doptelet) is an orally-active small molecule thrombopoietin (TPO) receptor agonist that was used for the first time in 2008 to treat patients with chronic idiopathic thrombocytopenic purpura. |
|
V3892 | Avatrombopag maleate | 677007-74-8 | Avatrombopag maleate (formerly AKR501, YM477, AS1670542; E5501;AKR-501, YM-477, AS-1670542; E-5501;Doptelet), the maleate salt ofAvatrombopag, is an orally bioactive thrombopoietin (TPO) receptor agonist approved in 2008 to treat patients with chronic idiopathic thrombocytopenic purpura. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
